Quantum-Si Inc is a life sciences company focused on proteomics research and analytical technologies. It develops single-molecule detection platforms designed to enable next-generation protein sequencing (NGPS) and large-scale protein analysis. Its technology supports massively parallel sequencing of proteins and can also be applied to the study of nucleic acids, providing tools for researchers and clinical applications in molecular analysis. The company's revenue is derived from sales of products and services.
Last trade$1.01
Day change-$0.055 (-5.19%)
Day range$0.993 – $1.08
Volume3,967,680
Market cap$233M
OpenXNAS
Fundamentals
Key company ratios and reported financial statements.
Source: Massive.com
Key ratios
Valuation
Market capitalization
$232.93M
Price / earnings
—
Price / book
1.45×
Price / sales
184.13×
EV / sales
163.91×
EV / EBITDA
-2.31×
Profitability
Earnings per share
-$0.39
Return on assets
-49.24%
Return on equity
-53.13%
Dividend yield
0%
Liquidity and leverage
Debt / equity
0×
Current ratio
9.64×
Quick ratio
9.5×
Cash ratio
2.19×
Cash flow
Price / cash flow
—
Price / free cash flow
—
Free cash flow
-$81.35M
Ratios use trailing-twelve-month financials and market data as of
Nov 16, 2026.
Financial statements
Income and cash flow amounts are for the period; balance sheets are point-in-time
snapshots. Amounts are shown in USD. Latest 8 quarterly or 5 annual periods are
displayed when available.
Income statement for QSI, quarterly periods
Line item
Q3 FY2026 Sep 30, 2026
Q2 FY2026 Jun 30, 2026
Q1 FY2026 Mar 31, 2026
Q4 FY2025 Dec 31, 2025
Q3 FY2025 Sep 30, 2025
Q2 FY2025 Jun 30, 2025
Q1 FY2025 Mar 31, 2025
Q4 FY2024 Dec 31, 2024
Revenue
$212K
$344K
$258K
$451K
$552K
$591K
$842K
$1.19M
Cost of revenue
$138K
$172K
$184K
$329K
$358K
$240K
$356K
$582K
Gross profit
$74K
$172K
$74K
$122K
$194K
$351K
$486K
$610K
Selling, general and administrative
$10.07M
$9.98M
$9.64M
$10.27M
$10.71M
$11.9M
$11.88M
$14.3M
Research and development
$13.78M
$15.82M
$14.49M
$10.95M
$13.88M
$15.21M
$13.72M
$16.99M
Total operating expenses
$23.85M
$25.8M
$24.13M
$21.22M
$26.39M
$30.47M
$25.6M
$31.29M
Operating income
-$23.78M
-$25.63M
-$24.05M
-$21.09M
-$26.2M
-$30.12M
-$25.11M
-$30.68M
Interest expense
$0
$0
$0
$0
$0
$0
$0
$0
Income before taxes
-$22.32M
-$23.53M
-$21.79M
-$17.6M
-$35.68M
-$28.82M
-$19.18M
-$33.11M
Income taxes
$0
$0
-$122K
$8K
$19K
$20K
$11K
$13K
Net income
-$22.32M
-$23.53M
-$21.67M
-$17.61M
-$35.7M
-$28.84M
-$19.19M
-$33.12M
Net income attributable to common shareholders
-$22.32M
-$23.53M
-$21.67M
-$17.61M
-$35.7M
-$28.84M
-$19.19M
-$33.12M
EBITDA
-$22.61M
-$24.4M
-$22.83M
-$19.92M
-$25.02M
-$28.93M
-$24.2M
-$29.68M
Basic earnings per share
-$0.10
-$0.11
-$0.10
-$0.08
-$0.17
-$0.16
-$0.11
-$0.23
Diluted earnings per share
-$0.10
-$0.11
-$0.10
-$0.08
-$0.17
-$0.16
-$0.11
-$0.23
Recent news
Company coverage with links to the original publishers.
Quantum-Si Incorporated announced the grant of 495,335 restricted stock units to new employees under its 2023 Inducement Equity Incentive Plan. The RSUs will vest 25% on December 20, 2027, with the remainder vesting quarterly thereafter, subject to continued employment. The company's Proteus platform remains on track for anticipated Q2 2027 commercial launch.
Quantum-Si Incorporated reported a Q3 loss of $0.10 per share, beating expectations of $0.13 loss, but significantly missed revenue estimates with $0.21 million versus consensus. Revenues declined 62% year-over-year from $0.55 million. The company received a Zacks Rank #3 (Hold) rating with mixed estimate revisions. Despite outperforming the S&P 500 by 5% year-to-date, the stock faces headwinds from weak revenue performance.
Quantum-Si Incorporated announced it will report Q3 2026 financial results and provide a business update on November 5, 2026, with a conference call hosted by President and CEO Jeff Hawkins and CFO Jeff Keyes at 4:30 PM ET. The company will webcast the event live on its investor relations website.
Quantum-Si announced interim development results for its next-generation Proteus platform, showing significant performance improvements over its commercially available Platinum Pro instrument. In control peptide studies, Proteus delivered 30 times more alignments per single chamber, achieved a 4.8-fold lower false discovery rate, and identified 1.6-2.0 times more peptides in protein mixtures. The company projects a full four-chamber Proteus run could deliver approximately 60 times more alignments than a two-chamber Platinum Pro run. Proteus is expected to launch in Q2 2027.
Quantum-Si filed a shelf registration with the SEC to potentially raise up to $300 million through various securities, causing investor concern about potential stock dilution and leading to a nearly 5% stock price decline.
Dividends
Declared distributions and recorded event dates. Forecasts are not
shown.
Updated daily
No declared upcoming dividend found.
No prior dividend records found.
Stock splits
Historical share-structure events and their execution dates.